Kirkos (Ethinylestradiol, Etonogestrel)

The two hormones bind to estrogen and progesterone receptors, suppressing the release of gonadotropins from the pituitary gland. This blocks follicular development and ovulation, while the progestogen thickens cervical mucus and alters the endometrium, creating multiple barriers to fertilisation and implantation.

The dosage and duration of Kirkos are set by the prescribing clinician based on the product’s approved labeling and the individual patient’s health profile. Patients should follow the prescriber’s instructions and not alter the ring’s use without medical advice.

Kirkos is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women and should be discontinued if pregnancy occurs. It is also not recommended for breastfeeding mothers because hormonal exposure may affect milk production and infant safety.

To order Kirkos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Kirkos offers a vaginal‑ring delivery system, which provides continuous hormone release for three weeks, unlike daily oral pills. Compared with other combined contraceptive rings, it has a similar efficacy profile but differs in hormone composition and packaging. Choice depends on patient preference, tolerability and clinical considerations.

Kirkos should be stored at room temperature, below 25 °C, in its original packaging. Keep the ring away from moisture, direct sunlight and extreme heat. Do not refrigerate or freeze the product, and handle it with clean, dry hands to maintain sterility.

The vaginal ring is inserted by the user into the upper vagina, where it remains in place for three weeks. After three weeks, the ring is removed, the user takes a one‑week ring‑free interval, and a new ring is then inserted to continue contraception.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Other rare but severe reactions can be severe allergic responses, liver dysfunction, and visual disturbances. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Kirkos is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or who smoke cigarettes and are over 35 years old. It should also be avoided in individuals with known hypersensitivity to any component of the ring.